CLDN2 and colorectal carcinoma: Glycosaminoglycans have therapeutic value in cancer [56]; tight junction whose protein claudin-2 has been reported as a potential target for CRC therapy [57]; circadian rhythm plays roles in the pathogenesis of CRC [58]; ECM-receptor interaction may play a critical role in CRC metastasis [59].